Brief: Onxeo FY Net Loss Widens To 33.8 Million Euros

Valerio Therapeutics SA

17/04/2020 17:15

April 17 (Reuters) - ONXEO SA  C4X.PA :
    * CASH POSITION OF €7 MILLION AT DECEMBER 31, 2019, COMBINED
WITH
$6.6 MILLION FROM NEW AGREEMENT WITH ACROTECH, PROVIDE EXTENDED
FINANCIAL VISIBILITY INTO Q2 2021
    * FY REVENUE EUR 4.3 MILLION VERSUS EUR 6.1 MILLION YEAR AGO
    * FY OPERATING LOSS EUR 9.8 MILLION VERSUS LOSS EUR 3.5
MILLION
YEAR AGO
    * FY NET LOSS EUR 33.8 MILLION VERSUS LOSS EUR 9.4 MILLION
YEAR
AGO
    * AT DECEMBER 31, CONSOLIDATED CASH POSITION OF EUR 5.7
MILLION
VERSUS EUR 11.3 MILLION YEAR AGO
    * ON CORONAVIRUS: IMPACT OF COVID-19 ON COMPANY'S OPERATIONS
ARE
LIMITED, ASSUMING SITUATION IMPROVES IN Q3 2020
    * ON CORONAVIRUS: IT IS NOT YET POSSIBLE TO ESTIMATE THE
FINAL
DELAYS
    * TOPLINE RESULTS FROM DRIIV-1B STUDY OF ASIDNA IN
COMBINATION
WITH REFERENCE CHEMOTHERAPY IN MULTI-TREATED ADVANCED SOLID
TUMORS EXPECTED BY END 2020
    * ASIDNA TO ADVANCE TO PHASE 1B/2 STUDY REVOCAN IN
COMBINATION
WITH NIRAPARIB IN PATIENTS WITH RELAPSED OVARIAN CANCER TO
EVALUATE EFFECT ON ACQUIRED RESISTANCE WITH PRELIMINARY DATA
POSSIBLY BY END 2020/EARLY 2021


Source text for Eikon:  ID:nNDL5B3R2n 
Further company coverage:  C4X.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))